Stockreport

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Pharmaceuticals Incorporated  (LGND) 
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.ligand.com
PDF Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $2 [Read more]